[WEBINAR] Automating Ancillary Processes  image

[WEBINAR] Automating Ancillary Processes

Closing the New Bottleneck in Cell and Gene Therapy Manufacturing 
Manual media formulation and viral vector packaging are time-intensive, tedious, and expensive activities. While cell and gene therapy manufacturers focus on closing core manufacturing processes, ancillary processes such as media formulation and viral vector packaging may remain open. These open processes introduce challenges in a GMP setting such as a higher risk of contamination, increased processing time, process variability, low throughput and the necessity for higher room classification or isolators.  
In this interactive webinar, the speakers shared their thoughts on challenges encountered when closing and automating ancillary processes, and how improved scalability and reproducibility were achieved by moving to closed automated platforms. They also discussed what industry standards could help to make large-scale media formulation and viral vector packaging more accessible to cell and gene therapy manufacturers. 
Access the on-demand recording to hear about: 
  • The challenges and benefits of moving media formulation and viral vector packaging from manual to automated systems 
  • Reducing process variability and risk 
  • Potential future changes that could simplify large-scale media formulation and viral vector packaging 
  • Economic considerations when evaluating trade-offs of moving to closing formulation and fill systems

  David Hodl
  Head of Business Development
  Amy Shaw
  Lead, Cell Therapies Engineering and Automation Development
  Randy Schweickart
  Senior Director, Process Technology Development
  Bristol Myers Squibb 
  Farid Ighemat
  Sr. Director, Manufacturing, Cell and Gene Therapy – R&D

To access the on-demand video recording, sign up below!